Mirko Marabese

2.3k total citations · 1 hit paper
54 papers, 1.6k citations indexed

About

Mirko Marabese is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Mirko Marabese has authored 54 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Molecular Biology, 25 papers in Oncology and 20 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Mirko Marabese's work include Lung Cancer Treatments and Mutations (20 papers), RNA modifications and cancer (12 papers) and Cancer-related Molecular Pathways (12 papers). Mirko Marabese is often cited by papers focused on Lung Cancer Treatments and Mutations (20 papers), RNA modifications and cancer (12 papers) and Cancer-related Molecular Pathways (12 papers). Mirko Marabese collaborates with scholars based in Italy, United States and Greece. Mirko Marabese's co-authors include Massimo Broggini, Elisa Caiola, Marina Chiara Garassino, Monica Ganzinelli, Eliana Rulli, Gabriella Farina, Faina Vikhanskaya, Valter Torri, Anna Bettini and Calogero Lauricella and has published in prestigious journals such as Nucleic Acids Research, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Mirko Marabese

51 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial

2013 376 citations Marina Chiara Garassino, Massimo Broggini et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mirko Marabese Italy	23	913	822	638	369	123	54	1.6k
Rhonda L. Bitting United States	18	747 0.8×	878 1.1×	930 1.5×	731 2.0×	85 0.7×	62	2.0k
Roberta Caputo Italy	13	612 0.7×	805 1.0×	664 1.0×	317 0.9×	94 0.8×	27	1.4k
Cordula Petersen Germany	26	1.0k 1.1×	870 1.1×	435 0.7×	493 1.3×	62 0.5×	60	2.0k
Cataldo Bianco Italy	24	757 0.8×	765 0.9×	427 0.7×	252 0.7×	110 0.9×	37	1.5k
Sabine Zumstein-Mecker Switzerland	9	767 0.8×	544 0.7×	394 0.6×	174 0.5×	105 0.9×	12	1.2k
Armelle Degeorges France	18	747 0.8×	776 0.9×	404 0.6×	562 1.5×	94 0.8×	34	1.6k
Chiara Lazzari Italy	24	580 0.6×	883 1.1×	738 1.2×	313 0.8×	103 0.8×	67	1.5k
Jean‐Claude Cutz Canada	20	666 0.7×	403 0.5×	370 0.6×	319 0.9×	69 0.6×	45	1.1k
Patrick J. Grohar United States	19	1.1k 1.2×	444 0.5×	623 1.0×	234 0.6×	246 2.0×	45	1.7k
Ludmilla Thomé Domingos Chinen Brazil	19	1.1k 1.2×	811 1.0×	448 0.7×	971 2.6×	90 0.7×	58	2.0k

Countries citing papers authored by Mirko Marabese

Since Specialization

Citations

This map shows the geographic impact of Mirko Marabese's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mirko Marabese with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mirko Marabese more than expected).

Fields of papers citing papers by Mirko Marabese

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mirko Marabese. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mirko Marabese. The network helps show where Mirko Marabese may publish in the future.

Co-authorship network of co-authors of Mirko Marabese

This figure shows the co-authorship network connecting the top 25 collaborators of Mirko Marabese. A scholar is included among the top collaborators of Mirko Marabese based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mirko Marabese. Mirko Marabese is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Moro, Massimo, Chiara Grasselli, Nicolò Panini, et al.. (2024). Caloric restriction and metformin selectively improved LKB1-mutated NSCLC tumor response to chemo- and chemo-immunotherapy. Journal of Experimental & Clinical Cancer Research. 43(1). 6–6. 11 indexed citations

Guffanti, Federica, Giulia Vargiu, Edoardo Micotti, et al.. (2024). Detection of aberrant locomotor activity in a mouse model of lung cancer via home cage monitoring. Frontiers in Oncology. 14. 1504938–1504938.

Corsetto, Paola Antonia, Angela Maria Rizzo, Mirko Marabese, et al.. (2022). NSCLC Cells Resistance to PI3K/mTOR Inhibitors Is Mediated by Delta-6 Fatty Acid Desaturase (FADS2). Cells. 11(23). 3719–3719. 4 indexed citations

Marabese, Mirko, et al.. (2022). LKB1: Can We Target an Hidden Target? Focus on NSCLC. Frontiers in Oncology. 12. 889826–889826. 14 indexed citations

Ganzinelli, Monica, Helena Linardou, M.F. Alvisi, et al.. (2021). Single-arm, open label prospective trial to assess prediction of the role of ERCC1/XPF complex in the response of advanced NSCLC patients to platinum-based chemotherapy. ESMO Open. 6(1). 100034–100034. 2 indexed citations

Marabese, Mirko, et al.. (2020). Activity of Birinapant, a SMAC Mimetic Compound, Alone or in Combination in NSCLCs With Different Mutations. Frontiers in Oncology. 10. 532292–532292. 8 indexed citations

Caiola, Elisa, Federica Guffanti, Edoardo Micotti, et al.. (2019). LKB1 Deficiency Renders NSCLC Cells Sensitive to ERK Inhibitors. Journal of Thoracic Oncology. 15(3). 360–370. 27 indexed citations

Caiola, Elisa, et al.. (2018). Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib. Scientific Reports. 8(1). 948–948. 24 indexed citations

Caiola, Elisa, Francesca Falcetta, Silvia Giordano, et al.. (2018). Co-occurring KRAS mutation/LKB1 loss in non-small cell lung cancer cells results in enhanced metabolic activity susceptible to caloric restriction: an in vitro integrated multilevel approach. Journal of Experimental & Clinical Cancer Research. 37(1). 302–302. 27 indexed citations

10.

Imbimbo, Martina, Milena Vitali, Alessandra Fabbri, et al.. (2018). RELEVENT Trial: Phase II Trial of Ramucirumab, Carboplatin, and Paclitaxel in Previously Untreated Thymic Carcinoma/B3 Thymoma With Area of Carcinoma. Clinical Lung Cancer. 19(5). e811–e814. 15 indexed citations

11.

Curatolo, Anais Del, Fabiana Conciatori, Ursula Cesta Incani, et al.. (2018). Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models. Journal of Experimental & Clinical Cancer Research. 37(1). 140–140. 32 indexed citations

12.

Moro, Massimo, Elisa Caiola, Monica Ganzinelli, et al.. (2018). Metformin Enhances Cisplatin-Induced Apoptosis and Prevents Resistance to Cisplatin in Co-mutated KRAS/LKB1 NSCLC. Journal of Thoracic Oncology. 13(11). 1692–1704. 80 indexed citations

13.

Marabese, Mirko, Elisa Caiola, Marina Chiara Garassino, et al.. (2016). G48A, a New KRAS Mutation Found in Lung Adenocarcinoma. Journal of Thoracic Oncology. 11(7). 1170–1175. 5 indexed citations

14.

Rulli, Eliana, Federica Guffanti, Elisa Caiola, et al.. (2016). The 5′UTR variant of ERCC5 fails to influence outcomes in ovarian and lung cancer patients undergoing treatment with platinum-based drugs. Scientific Reports. 6(1). 39217–39217. 5 indexed citations

15.

Piva, Sheila, Monica Ganzinelli, Marina Chiara Garassino, et al.. (2014). Across the Universe of K-Ras Mutations in Non-Small-Cell-Lung Cancer. Current Pharmaceutical Design. 20(24). 3933–3943. 27 indexed citations

16.

Caiola, Elisa, Eliana Rulli, Robert Fruscio, et al.. (2012). KRas-LCS6 polymorphism does not impact on outcomes in ovarian cancer.. PubMed Central. 10 indexed citations

17.

Caiola, Elisa, Luca Porcu, Robert Fruscio, et al.. (2011). DNA-damage response gene polymorphisms and therapeutic outcomes in ovarian cancer. The Pharmacogenomics Journal. 13(2). 159–172. 16 indexed citations

18.

Marabese, Mirko, Sergio Marchini, Dario Cattaneo, et al.. (2007). Expression levels of p53 and p73 isoforms in stage I and stage III ovarian cancer. European Journal of Cancer. 44(1). 131–141. 29 indexed citations

19.

Marabese, Mirko, Sergio Marchini, Maria Antonietta Sabatino, et al.. (2005). Effects of inducible overexpression of DNp73α on cancer cell growth and response to treatment in vitro and in vivo. Cell Death and Differentiation. 12(7). 805–814. 17 indexed citations

20.

Marabese, Mirko. (2003). DNA damage induces transcriptional activation of p73 by removing C-EBP repression on E2F1. Nucleic Acids Research. 31(22). 6624–6632. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact